Provided by Tiger Trade Technology Pte. Ltd.

HANSOH PHARMA

31.540
-0.640-1.99%
Volume:9.96M
Turnover:314.16M
Market Cap:191.26B
PE:28.92
High:32.860
Open:32.380
Low:31.180
Close:32.180
52wk High:43.587
52wk Low:27.658
Shares:6.06B
HK Float Shares:6.06B
Volume Ratio:1.25
T/O Rate:0.16%
Dividend:0.50
Dividend Rate:1.57%
EPS(LYR):1.091
ROE:19.40%
ROA:9.08%
PB:4.32
PE(LYR):28.92
PS:10.26

Loading ...

Hansoh Pharmaceutical - Clinical Trial Approvals for Hs-20136-2 Injection Issued- by Nmpa

THOMSON REUTERS
·
Jul 02

Hansoh Pharmaceutical Group Stock Rises 6.4% in Hong Kong

Dow Jones
·
Jul 02

Movement Alert|Hansoh Pharmaceutical Rises 6.01% in Regular Trading, Pemosatide Injection Approval Coupled with Pharma Sector Rally

Market Focus
·
Jul 02

Hansoh Pharmaceutical Group Stock Falls 2.3% in Hong Kong

Dow Jones
·
Jun 30

Movement Alert|Hansoh Pharmaceutical Falls 3.03% in Regular Trading, Pharmaceutical Sector Under Broad Selling Pressure

Market Focus
·
Jun 30

Hansoh Pharmaceutical Group Stock Rises 5.8% in Hong Kong

Dow Jones
·
Jun 29

Movement Alert|Hansoh Pharmaceutical Rises 4.88% in Regular Trading, Pharma Sector Rally Combines with Dense Pipeline Catalysts

Market Focus
·
Jun 29

Hansoh Pharma Shareholders Approved 2026 Share Scheme at AGM

Reuters
·
Jun 26

Hansoh Pharmaceutical Group Stock Slides 1.3% in Hong Kong

Dow Jones
·
Jun 24

Movement Alert|Hansoh Pharmaceutical Rises 3.18% in Regular Trading, Receives Inaugural Buy Rating from Guosheng Securities

Market Focus
·
Jun 24

Hansoh Pharmaceutical Group (SEHK:3692) Stock Could Be Below Fair Value After Hang Seng Index Inclusion

Simply Wall St.
·
Jun 21

Hansoh Pharma releases in vitro study data on HS-20094 dual-biased GLP-1/GIP agonist at ENDO 2026

Reuters
·
Jun 16

Hansoh Pharmaceutical Group Stock Rallies 2.6% in Hong Kong

Dow Jones
·
Jun 12

Hansoh Pharma posts 80% MMR at week 48 in phase 1b HS-10382 plus flumatinib trial for newly diagnosed CML-CP

Reuters
·
Jun 12

Hansoh Pharmaceutical Group (SEHK:3692) Valuation Check After Hang Seng China Enterprises Index Inclusion

Simply Wall St.
·
Jun 11

Hansoh Pharma Appoints Guo Ying as Joint Company Secretary Following Zhong Shengli’s Resignation

Bulletin Express
·
Jun 10

Hansoh Pharma’s NDA for HS-10568 Injection Accepted by China’s NMPA

Bulletin Express
·
Jun 10

HANSOH PHARMA Receives NMPA Acceptance for New Drug Application of HS-10568 Injection

Stock News
·
Jun 10

Hansoh Pharma says China regulator accepts NDA for HS-10568 injection in kidney disease complication

Reuters
·
Jun 10

Hansoh Pharmaceutical - Nda for Hs-10,568 Injection Accepted by Nmpa of China for Shpt in Adult Ckd Patients

THOMSON REUTERS
·
Jun 10